119 related articles for article (PubMed ID: 10742693)
21. Induction of Heterologous Tier 2 HIV-1-Neutralizing and Cross-Reactive V1/V2-Specific Antibodies in Rabbits by Prime-Boost Immunization.
Townsley S; Mohamed Z; Guo W; McKenna J; Cleveland B; LaBranche C; Beaumont D; Shen X; Yates NL; Pinter A; Tomaras GD; Ferrari G; Montefiori DC; Hu SL
J Virol; 2016 Oct; 90(19):8644-60. PubMed ID: 27440894
[TBL] [Abstract][Full Text] [Related]
22. A Trimeric HIV-1 Envelope gp120 Immunogen Induces Potent and Broad Anti-V1V2 Loop Antibodies against HIV-1 in Rabbits and Rhesus Macaques.
Jones AT; Chamcha V; Kesavardhana S; Shen X; Beaumont D; Das R; Wyatt LS; LaBranche CC; Stanfield-Oakley S; Ferrari G; Montefiori DC; Moss B; Tomaras GD; Varadarajan R; Amara RR
J Virol; 2018 Mar; 92(5):. PubMed ID: 29237847
[TBL] [Abstract][Full Text] [Related]
23. Multi-envelope HIV vaccine safety and immunogenicity in small animals and chimpanzees.
Lockey TD; Slobod KS; Caver TE; D'Costa S; Owens RJ; McClure HM; Compans RW; Hurwitz JL
Immunol Res; 2000; 21(1):7-21. PubMed ID: 10803879
[TBL] [Abstract][Full Text] [Related]
24. Importance of conformation on the neutralizing antibody response to HIV-1 gp120.
Steimer KS; Haigwood NL
Biotechnol Ther; 1991; 2(1-2):63-89. PubMed ID: 1726963
[TBL] [Abstract][Full Text] [Related]
25. Does the key to a successful HIV type 1 vaccine lie among the envelope sequences of infected individuals?
Rencher SD; Slobod KS; Dawson DH; Lockey TD; Hurwitz JL
AIDS Res Hum Retroviruses; 1995 Sep; 11(9):1131-3. PubMed ID: 8554911
[No Abstract] [Full Text] [Related]
26. Immunization with recombinant canarypox vectors expressing membrane-anchored glycoprotein 120 followed by glycoprotein 160 boosting fails to generate antibodies that neutralize R5 primary isolates of human immunodeficiency virus type 1.
Bures R; Gaitan A; Zhu T; Graziosi C; McGrath KM; Tartaglia J; Caudrelier P; El Habib R; Klein M; Lazzarin A; Stablein DM; Deers M; Corey L; Greenberg ML; Schwartz DH; Montefiori DC
AIDS Res Hum Retroviruses; 2000 Dec; 16(18):2019-35. PubMed ID: 11153085
[TBL] [Abstract][Full Text] [Related]
27. HIV gp120 vaccine (Chiron).
Drugs R D; 1999 Jun; 1(6):445-7. PubMed ID: 10566078
[No Abstract] [Full Text] [Related]
28. DNA vaccine molecular adjuvants SP-D-BAFF and SP-D-APRIL enhance anti-gp120 immune response and increase HIV-1 neutralizing antibody titers.
Gupta S; Clark ES; Termini JM; Boucher J; Kanagavelu S; LeBranche CC; Abraham S; Montefiori DC; Khan WN; Stone GW
J Virol; 2015 Apr; 89(8):4158-69. PubMed ID: 25631080
[TBL] [Abstract][Full Text] [Related]
29. Synthetic AIDS vaccine by targeting HIV receptor.
Wang CY; Shen M; Tam G; Fang XD; Ye J; Shen F; Walfield AM; Wang JJ; Li ML; Li XM; Salas M; Shearer MH; Kennedy RC; Hanson CV
Vaccine; 2002 Nov; 21(1-2):89-97. PubMed ID: 12443666
[TBL] [Abstract][Full Text] [Related]
30. Cytotoxic T cell and neutralizing antibody responses to human immunodeficiency virus type 1 envelope with a combination vaccine regimen. AIDS Vaccine Evaluation Group.
Corey L; McElrath MJ; Weinhold K; Matthews T; Stablein D; Graham B; Keefer M; Schwartz D; Gorse G
J Infect Dis; 1998 Feb; 177(2):301-9. PubMed ID: 9466515
[TBL] [Abstract][Full Text] [Related]
31. Induction of antibodies to the human immunodeficiency virus type 1 by immunization of baboons with immunoglobulin molecules carrying the principal neutralizing determinant of the envelope protein.
Zaghouani H; Anderson SA; Sperber KE; Daian C; Kennedy RC; Mayer L; Bona CA
Proc Natl Acad Sci U S A; 1995 Jan; 92(2):631-5. PubMed ID: 7831341
[TBL] [Abstract][Full Text] [Related]
32. Safety and immunogenicity of an HLA-based HIV envelope polyvalent synthetic peptide immunogen. DATRI 010 Study Group. Division of AIDS Treatment Research Initiative.
Bartlett JA; Wasserman SS; Hicks CB; Dodge RT; Weinhold KJ; Tacket CO; Ketter N; Wittek AE; Palker TJ; Haynes BF
AIDS; 1998 Jul; 12(11):1291-300. PubMed ID: 9708408
[TBL] [Abstract][Full Text] [Related]
33. An HIV Envelope gp120-Fc Fusion Protein Elicits Effector Antibody Responses in Rhesus Macaques.
Shubin Z; Li W; Poonia B; Ferrari G; LaBranche C; Montefiori D; Zhu X; Pauza CD
Clin Vaccine Immunol; 2017 Jun; 24(6):. PubMed ID: 28404572
[TBL] [Abstract][Full Text] [Related]
34. A phase II study of two HIV type 1 envelope vaccines, comparing their immunogenicity in populations at risk for acquiring HIV type 1 infection. AIDS Vaccine Evaluation Group.
McElrath MJ; Corey L; Montefiori D; Wolff M; Schwartz D; Keefer M; Belshe R; Graham BS; Matthews T; Wright P; Gorse G; Dolin R; Berman P; Francis D; Duliege AM; Bolognesi D; Stablein D; Ketter N; Fast P
AIDS Res Hum Retroviruses; 2000 Jun; 16(9):907-19. PubMed ID: 10875616
[TBL] [Abstract][Full Text] [Related]
35. Evaluation of a synthetic vaccine construct as antigen for the detection of HIV-induced humoral responses.
Hewer R; Meyer D
Vaccine; 2005 Mar; 23(17-18):2164-7. PubMed ID: 15755588
[TBL] [Abstract][Full Text] [Related]
36. Screening of primary gp120 immunogens to formulate the next generation polyvalent DNA prime-protein boost HIV-1 vaccines.
Wang S; Chou TH; Hackett A; Efros V; Wang Y; Han D; Wallace A; Chen Y; Hu G; Liu S; Clapham P; Arthos J; Montefiori D; Lu S
Hum Vaccin Immunother; 2017 Dec; 13(12):2996-3009. PubMed ID: 28933684
[TBL] [Abstract][Full Text] [Related]
37. Immunogenicity of a vaccine preparation representing the variable regions of the HIV type 1 envelope glycoprotein.
Carlos MP; Anderson DE; Gardner MB; Torres JV
AIDS Res Hum Retroviruses; 2000 Jan; 16(2):153-61. PubMed ID: 10659054
[TBL] [Abstract][Full Text] [Related]
38. Genetic and immunologic characterization of viruses infecting MN-rgp120-vaccinated volunteers.
Berman PW; Gray AM; Wrin T; Vennari JC; Eastman DJ; Nakamura GR; Francis DP; Gorse G; Schwartz DH
J Infect Dis; 1997 Aug; 176(2):384-97. PubMed ID: 9237703
[TBL] [Abstract][Full Text] [Related]
39. Lack of induction of antibodies specific for conserved, discontinuous epitopes of HIV-1 envelope glycoprotein by candidate AIDS vaccines.
VanCott TC; Bethke FR; Burke DS; Redfield RR; Birx DL
J Immunol; 1995 Oct; 155(8):4100-10. PubMed ID: 7561123
[TBL] [Abstract][Full Text] [Related]
40. Increased immunogenicity of HIV envelope subunit complexed with alpha2-macroglobulin when combined with monophosphoryl lipid A and GM-CSF.
Liao HX; Cianciolo GJ; Staats HF; Scearce RM; Lapple DM; Stauffer SH; Thomasch JR; Pizzo SV; Montefiori DC; Hagen M; Eldridge J; Haynes BF
Vaccine; 2002 May; 20(17-18):2396-403. PubMed ID: 12009296
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
